Johnson & Johnson subsidiary OrthoNeutrogena has agreed to buy Israel's Colbar LifeScience, which specializes in reconstructive medicine and tissue engineering. J&J announced it would take a $50 million charge related to the deal, but no other details were announced. Colbar markets a couple of products, including a collagen treatment and a dental membrane that assists in regenerating bones.
- here's the report on the deal from Trading Markets